Targets › COMP
1 program from 1 company in 4 trials: 2 Phase 3, 2 Phase 2; Neurology; next expected readout Dec 2026.
Plays a role in the structural integrity of cartilage via its interaction with other extracellular matrix proteins such as the collagens and fibronectin. Can mediate the interaction of chondrocytes with the cartilage extracellular matrix through interaction with cell surface integrin receptors. (UniProt, P49747)
Open in Phaseline: the race on COMP, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Dianthus Therapeutics | Claseprubart complement C5 inhibitor | FCER2, COMP | Phase 3 | Myasthenia Gravis, Generalized; Chronic Inflammatory Demyelinating Polyneuropathy; Multifocal Motor Neuropathy | Dec 2026 |
Myasthenia Gravis, Generalized (2) Chronic Inflammatory Demyelinating Polyneuropathy (1) Multifocal Motor Neuropathy (1)
antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.